补肾通脉方对急性ST段抬高型心肌梗死PCI术后凝血-纤溶系统及血脂的影响  

Effect of Bushen Tongmai Prescription on Coagulation and Fibrinolysis System and Blood Lipid after PCI of Acute ST Segment Elevation Myocardial Infarction

作　　者：张庆[1] 姚姗姗 黄晶晶[1] 刘孟[1] 刘敏[1] 卢磊[1] 梁田[1] ZHANG Qing;YAO Shanshan;HUANG Jingjing;LIU Meng;LIU Min;LU Lei;LIANG Tian(Xuzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Xuzhou 221000,China;不详)

机构地区：[1]南京中医药大学附属徐州中医院,江苏徐州221000

出　　处：《中外医学研究》2024年第5期44-48,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：徐州市中医药科技发展计划项目(XZYB2021003)。

摘　　要：目的:观察补肾通脉方对急性ST段抬高型心肌梗死经皮冠状动脉介入术(PCI)术后凝血-纤溶系统及血脂的影响。方法:选取2017年3月—2020年3月南京中医药大学附属徐州中医院收治的92例急性ST段抬高型心肌梗死患者,按照随机分组的方法,将其分为对照组和治疗组,各46例。入组患者均给予标准化内科治疗,治疗组在标准治疗的基础上加用补肾通脉方。观察两组治疗前后纤维蛋白原(FIB)、抗凝血酶Ⅲ(AT-Ⅲ)、组织型纤溶酶原激活物(t-PA)、纤溶酶原活化物抑制剂1(PAI-1)、可溶性白细胞分化抗原40配体(sCD40L)、可溶性细胞间黏附因子-1(sICAM-1)及血脂的变化。结果:治疗前,两组FIB、AT-Ⅲ、t-PA、PAI-1水平比较,差异无统计学意义(P>0.05);治疗后,两组FIB、PAI-1水平下降,AT-Ⅲ、t-PA水平升高,治疗组FIB、PAI-1水平低于对照组,AT-Ⅲ、t-PA水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组sCD40L、sICAM-1水平比较,差异无统计学意义(P>0.05);治疗后,两组sCD40L、sICAM-1水平均显著下降,治疗组sCD40L、sICAM-1水平低于对照组,差异有统计学意义(P<0.05)。治疗前,两组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后,两组TC、TG、LDL-C水平均显著下降,HDL-C升高,治疗组TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。结论:在标准化内科治疗基础上加用补肾通脉方能够改善急性ST段抬高型心肌梗死患者PCI术后高凝状态,调节患者体内凝血-纤溶系统平衡,控制炎症反应,降低血脂水平。Objective:To observe the effects of Bushen Tongmai Prescription on coagulation and fibrinolysis system and blood lipid after percutaneous coronary intervention(PCI)of acute ST segment elevation myocardial infarction.Method:Ninety-two patients with acute ST-segment elevation myocardial infarction admitted to Xuzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine from March 2017 to March 2020 were selected,and they were divided into control group and treatment group according to random grouping method,with 46 cases in each group.All enrolled patients were given standardized medical treatment,and Bushen Tongmai Prescription was added to the treatment group on the basis of standard treatment.The changes of fibrinogen(FIB),antithrombinⅢ(AT-Ⅲ),tissue type plasminogen activator(t-PA),plasminogen activator inhibitor 1(PAI-1),soluble leukocyte differentiation antigen 40 ligand(sCD40L),soluble intercellular adhesion factor-1(sICAM-1)and blood lipid before and after treatment were observed in the two groups.Result:Before treatment,there were no significant differences in FIB,AT-Ⅲ,t-PA and PAI-1 levels between the two groups(P>0.05).After treatment,FIB and PAI-1 levels decreased,AT-Ⅲand t-PA levels increased,FIB and PAI-1 levels in the treatment group were lower than those in the control group,while AT-Ⅲand t-PA levels were higher than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in sCD40L and sICAM-1 levels between the two groups(P>0.05).After treatment,the levels of sCD40L and sICAM-1 in both groups decreased significantly,and the levels of sCD40L and sICAM-1 in the treatment group were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C)bet

关 键 词：补肾通脉方 凝血-纤溶系统 可溶性白细胞分化抗原40配体 可溶性细胞间黏附因子-1 血脂 

分 类 号：R259[医药卫生—中西医结合]